A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)
Completed · Phase 2 · NCT04867616
Conditions: Alzheimer's Disease
At a glance
- Research payments reported, 2025
- $467,527
- U.S. investigators named
- 18
- Sites paid
- 19
- Planned or actual enrollment
- 466
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- Placebo (other), Bepranemab (biological)
- Dates
- Started 2021-06-09; completion 2025-08-01
- Results posted
- Not yet
The purpose of the study is to investigate the effect of bepranemab versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's Disease (AD).
From ClinicalTrials.gov, last updated 2026-07-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $467,527 in research payments for this study in 2025 (19 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Perminder Bhatia, MD Neurology · Fresno, CA
- Paulette R. Cazares, M.D., MPH Internal Medicine · San Diego, CA
- Anthony M. Ciabarra, M.D., PH.D. Neurology · Fullerton, CA
- John G. Duffy, MD Psychiatry · Santa Ana, CA
- Christopher H. Vandyck, MD Psychiatry · New Haven, CT
- Raymond S. Turner, MD,PHD Neurology · Washington, DC
- Jose E. Gamez, M.D Psychiatry · Hialeah, FL
- William A. Justiz, MD Neurology · Naples, FL
- Michael M. Pfeffer, MD Neurology · Miami, FL
- Julie B. Schwartzbard, MD Neurology · Aventura, FL
- Alexander White, MD Family Medicine · Daytona Beach, FL
- Malini A. Nair, MD Psychiatry · Winchester, MA
- Marcel Hungs, MD Neurology · Saint Paul, MN
- Mark W. Ornstein, M.D. Internal Medicine · Farmingdale, NJ
- Rhonna Shatz, D.O. Neurology · West Chester, OH
- Paul E. Schulz, M.D. Neurology · Houston, TX
- Arifulla -. Khan, MD Psychiatry · Bellevue, WA
- Joseph A. Cahill, M.D. Neurology · Rhinelander, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- West Haven VA Medical Center $65,217
- Advanced Clinical Institute Inc. $44,938
- Healthpartners Research Foundation $43,180
- Inland Rheumatology and Osteoporosis Medical Group, Inc $38,580
- Panhandle Research and Medical Clinic LLC $36,708
- Northwest Clinical Research Center $32,092
- Aqualane Clinical Research LLC $30,932
- Yale University $30,281
- Lynn Health Science Institute Inc. $25,772
- Elias Research Associates $23,576
- Visionary Investigators Network $21,253
- Boston Neuropsychatry LLC $19,646
- Neuro PAin Medical Center Inc $12,445
- University of Cincinnati Physicians Inc LLC $11,482
- Sc3 Research Group Inc $8,968
- Re:cognition Health Corporation $8,782
- Raa Apex Acquisition LLC $6,720
- Sharp Memorial Hospital $3,500
- Progressive Medical Concepts LLC $3,455
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.